Skip to main content

Advertisement

Log in

Targeting LGR4–Wnt activates ferroptosis and reverses drug resistance in colorectal cancer

  • Research Briefing
  • Published:

From Nature Cancer

View current issue Submit your manuscript

Our study reveals that the LGR4–Wnt signaling pathway dictates both ferroptosis and stemness traits to confer drug resistance to tumor cells. We thus generated a monoclonal antibody against LGR4 that blocks LGR4–Wnt signaling and sensitizes chemotherapy-resistant colorectal cancer tumors via selective promotion of ferroptosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1: Schematic illustrating how LGR4-mAb sensitizes chemotherapeutic drug-resistant CRC PDOs.

References

  1. Ciardiello, F. et al. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA Cancer J. Clin. 72, 372–401 (2022). This review article presents advances in the clinical management of patients with CRC.

    Article  PubMed  Google Scholar 

  2. Takebe, N. et al. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat. Rev. Clin. Oncol. 12, 445–464 (2015). This review article presents important signaling pathways that regulate cancer stem cells and embryonic development.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Cheng, Q. et al. LGR4 cooperates with PrPc to endow the stemness of colorectal cancer stem cells contributing to tumorigenesis and liver metastasis. Cancer Lett. 540, 215725 (2022). This paper reports that CRC tumor cells with high expression of LGR4 and PrPc show all the traits of cancer stem cells.

    Article  CAS  PubMed  Google Scholar 

  4. Guo, J. et al. Ferroptosis: a novel anti-tumor action for cisplatin. Cancer Res. Treat. 50, 445–460 (2018). This paper reports that clinical chemotherapy drugs induce ferroptosis in cancer cells.

    Article  CAS  PubMed  Google Scholar 

  5. Friedmann Angeli, J. P., Krysko, D. V. & Conrad, M. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat. Rev. Cancer 19, 405–414 (2019). This review article presents important mechanisms adopted by cancers with acquired drug resistance to provide protection against vulnerability to ferroptosis.

    Article  CAS  PubMed  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Zheng, H. et al. Targeted activation of ferroptosis in colorectal cancer via LGR4 targeting overcomes acquired drug resistance. Nat. Cancer https://doi.org/10.1038/s43018-023-00715-8 (2024).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Targeting LGR4–Wnt activates ferroptosis and reverses drug resistance in colorectal cancer. Nat Cancer 5, 542–543 (2024). https://doi.org/10.1038/s43018-023-00714-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-023-00714-9

  • Springer Nature America, Inc.

Navigation